Volume 44 Issue 12, December 2023

Cover Credit: Schematic illustration of RVG-miR-23a/27a/26a-Exos for the treatment of diabetic nephropathy (DN). Delivery of miR-23a/27a/26a cluster by RVG-modified satellite cell-derived Exos could be a promising targeted treatment for DN. RVG-miR-23a/27a/26a-Exos could effectively ameliorate tubular injury and tubulointerstitial fibrosis (TIF) by a mechanism that synergistically targets several profibrotic regulators, which not only regulated miRNA cluster-targeting Lpp simultaneously, but controlled miR-27a-3p-targeting Zbtb20 and miR-26a-5p-targeting Klhl42, respectively. (DOI 10.1038/s41401-023-01140-4). See the article in pages 2455–2468